Click on a filter below to refine your search. Remove a filter to broaden your search.
No increase was seen in the incidence of hypotension episodes with replacement of salt by a potassium-enriched substitute.
Active treatment lowered SBP, improved 6-minute walk test and improved measures of endothelial function.
Utility companies expected to cover most of the cost, but there is $15 billion available in the 2021 infrastructure law to help
MPV ≥10.2 fL was independently associated with all-cause mortality and cardiovascular mortality.
The prevalence of stage 2 hypertension was about 30%; approximately 70% received treatment.
A decline in blood pressure from high- to low-sodium diet was independent of hypertension status; it generally was consistent across subgroups.
Higher blood pressure variability was not associated with higher lifetime dementia risk at age 60, 70 or 80 years.
Solriamfetol was found to be well-tolerated with no significant effect on mean heart rate or systolic or diastolic blood pressure.
Changes in office systolic BP of −14.1, −13.2, −6.9 and −4.1 mm Hg were seen with 100, 50, 12.5 mg once daily of lorundrostat and placebo.
An individual patient data meta-analysis shows increased risk for dementia for those with untreated hypertension.